Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

86 results about "Lysin" patented technology

Lysins, also known as endolysins or murein hydrolases, are hydrolytic enzymes produced by bacteriophages in order to cleave the host's cell wall during the final stage of the lytic cycle. Lysins are highly evolved enzymes that are able to target one of the five bonds in peptidoglycan (murein), the main component of bacterial cell walls, which allows the release of progeny virions from the lysed cell. Cell-wall-containing Archaea are also lysed by specialized pseudomurein-cleaving lysins, while most archaeal viruses employ alternate mechanisms. Similarly, not all bacteriophages synthesize lysins: some small single-stranded DNA and RNA phages produce membrane proteins that activate the host's autolytic mechanisms such as autolysins.

Nanoparticle compound for inhibiting bone and soft tissue infection as well as preparation method and application thereof

The invention provides a nanoparticle compound for inhibiting bone and soft tissue infection as well as a preparation method and application thereof, and belongs to the technical field of medical biological materials. The nanoparticle compound is a gentiopicroside, sericin, hyaluronic acid and endolysin liposome nanoparticle, and a gentiopicroside, sericin, hyaluronic acid and endolysin co-delivery nano drug delivery system targeting the S100A4 site is designed based on the target S100A4 closely related to bone infection through Ai molecular docking and nano drug delivery technologies. The nanoparticle compound provided by the invention has better stability and bioavailability, and can be used for improving and relieving inflammatory response and increasing wound healing effect.
Owner:JIANGXI SCI & TECH NORMAL UNIV

Marine bacteriophage antibacterial lysin prediction method, device, medium and equipment

The invention discloses a marine bacteriophage antibacterial lysin prediction method, device, medium and equipment, and relates to the field of biological medicine and computational biology. Comprising the following steps: constructing a training data set based on a globally known antibacterial protein sequence; and training a protein sequence classification model based on deep learning by using the antibacterial protein data set to obtain a marine antibacterial lysin prediction model. The method comprises the following steps: carrying out data standardization processing on a to-be-predicted bacteriophage protein sequence, inputting the to-be-predicted bacteriophage protein sequence into a protein language model, carrying out self-attention modeling on the input sequence through a ProtT5 module, and extracting global structure and function related features to obtain a first feature vector; extracting a short sequence local dependency feature through a ProtBERT module to obtain a second feature vector; performing weighted summation on the first feature vector and the second feature vector to generate a fusion feature vector; and carrying out probability prediction on the fusion feature vector, and outputting the antibacterial tag and the prediction confidence of the marine phage sequence to be predicted.
Owner:OCEAN UNIV OF CHINA

Engineered lysin polypeptide constructs active against gram-negative bacteria

The present disclosure is directed to an engineered lysin comprising: (a) a Gram-negative base lysin; and (b) one or more antimicrobial peptide (AMP) and / or cell penetrating peptide (CPP), and optionally an outer membrane binding motif and at least one linker, or an active fragment thereof, or a variant thereof having at least 80% sequence identity. Also disclosed herein are methods of treating a bacterial infection caused by at least one Gram-negative bacteria and methods of killing at least one Gram-negative bacteria, comprising administering the engineered lysin disclosed herein.
Owner:AUROBAC THERAPEUTICS SAS

Engineered lysin polypeptide constructs active against gram-negative bacteria

The present disclosure is directed to an engineered lysin comprising: (a) a Gram-negative base lysin; and (b) one or more antimicrobial peptide (AMP) and / or cell penetrating peptide (CPP), and optionally an outer membrane binding motif and at least one linker, or an active fragment thereof, or a variant thereof having at least 80% sequence identity. Also disclosed herein are methods of treating a bacterial infection caused by at least one Gram-negative bacteria and methods of killing at least one Gram-negative bacteria, comprising administering the engineered lysin disclosed herein.
Owner:AUROBAC THERAPEUTICS SAS

Antibody conjugates for targeting tumors expressing carcino-embryonic antigens

The present invention relates to antibody conjugates which are particularly suitable for targeting CEA-expressing cells, in particular tumor cells. An antibody conjugate according to the present invention has the structure (1): AB-[(L6) b-{Z-L-D} x] y (1) wherein AB is an antibody capable of targeting a tumor expressing CEA; l is a joint connecting Z to D; z is a linking group; l6 is-GlcNAc (Fuc) w-(G) j-S-(L7) w-wherein G is a monosaccharide, j is an integer in the range of 0 to 10, S is a sugar or a sugar derivative, GlcNAc is N-acetylglucosamine, and Fuc is fucose, w is 0 or 1, w'is 0, 1 or 2, and L7 is-N (H) C (O) CH2-,-N (H) C (O) CF2-or-CH2-; d is selected from the group consisting of an anthracycline, a camptothecin, a tubulysin, an endiyne, an amanitine, a duocarmycin, a maytansinoid, an aurestatin, eribulin, a BCL-XL inhibitor, a miscanthus hemiphyllum, a KSP inhibitor, a TLR agonist, an indolo-benzodiazepine # imgabs 0 # dimer or a pyrrolo-benzodiazepine # imgabs 1 # dimer (PBD), and analogs or prodrugs thereof; b is 0 or 1; x is 1 or 2; and y is 1, 2, 3 or 4. The invention further relates to a method for preparing said antibody conjugate of structure (1) and to the use of said antibody conjugate of structure (1).
Owner:EMERGING BIOTECHNOLOGY CO

Phage lyase and application thereof

The invention discloses a bacteriophage lyase and application thereof, and particularly relates to a bacteriophage lyase with an amino acid sequence as shown in SEQ INNO.2. The bacteriophage lyase can inhibit the growth of escherichia coli, staphylococcus and salmonella, can be used as an antibacterial substance in splitting gram-negative bacteria and can be used for preparing drugs for resisting gram-negative bacteria. The lyase can be used independently or compounded with other substances, the use concentration of antibiotics can be reduced by combining the lyase with the antibiotics, toxic and side effects (such as renal toxicity of polymyxin) of drugs are reduced, and meanwhile, generation of bacterial drug resistance is delayed. After the lyase and the chitosan are combined for use, remarkable antibacterial activity is generated, the antibacterial effect can be achieved without pre-treatment on bacteria, and the practicability is improved.
Owner:GUANGDONG MEDICAL UNIV

Antibody conjugates for targeting tumors expressing PTK7

The present invention relates to antibody conjugates which are particularly suitable for targeting cells expressing PTK7, in particular tumor cells. An antibody conjugate according to the present invention has structure (1): AB-[(L6) b-{Z-L-D} x] y (1) wherein AB is an antibody capable of targeting a tumor expressing PTK7; l is a joint connecting Z to D; z is a linking group; l6 is-GlcNAc (Fuc) w-(G) j-S-(L7) w '-wherein G is a monosaccharide, j is an integer in the range of 0 to 10, S is a sugar or a sugar derivative, GlcNAc is N-acetylglucosamine, and Fuc is fucose, w is 0 or 1, w' is 0, 1 or 2, and L7 is-N (H) C (O) CH2-,-N (H) C (O) CF2-or-CH2-; d is selected from the group consisting of an anthracycline, a camptothecin, a tubulysin, an endiyne, an amanitine, a duocarmycin, a maytansinoid, an aurestatin, eribulin, a BCL-XL inhibitor, a miscanthus semiaquilaria, a KSP inhibitor, a TLR agonist, an indolo-benzodiazepine dimer or a pyrrolo-benzodiazepine dimer (PBD), and an analog or prodrug thereof; b is 0 or 1; x is 1 or 2; and y is 1, 2, 3 or 4. The invention further relates to a method for preparing said antibody conjugate of structure (1) and to the use of said antibody conjugate of structure (1).
Owner:EMERGING BIOTECHNOLOGY CO

Piglet intestinal health targeting probiotic engineering bacterium compound as well as preparation and application thereof

The invention discloses a piglet intestinal health targeting probiotic engineering bacterium compound as well as preparation and application thereof. The compound is FP (at) EcN-pnirNKL, wherein a) the EcN-pnirNKL is an engineering strain which is constructed by taking escherichia coli Niss1917 (EcN) as a host and carrying a recombinant plasmid pnirBMisL-NK-Lysin, and a) the EcN-pnirNKL is an engineering strain which is constructed by taking escherichia coli Niss1917 (EcN) as a host and carrying a recombinant plasmid pnirBMisL-NK-Lysin; b) the recombinant plasmid pnirBMisL-NK-Lysin comprises an NK-Lysin gene optimized by a codon, and the NK-Lysin gene is integrated into the anaerobic inducible plasmid pnirBMisL through homologous recombination; c) the FP is a composite nano-particle which takes nano mesoporous silica (MSN) as a core and is formed by crosslinking fucoidin and rhodiola rosea polysaccharide; and d) the FP (at) EcN-pnirNKL is an oral delivery system which is formed by encapsulating the engineering bacterium EcN-pnirNKL in the FP nano particles. When the compound is applied to prevention and treatment of stress response of weaned piglets, various typical symptoms, including weight loss, colon shortening, histopathological injury and colitis disease response, of the piglets induced by dextran sodium sulfate can be remarkably relieved, and meanwhile, the integrity and functions of an intestinal barrier structure are effectively protected.
Owner:ZHEJIANG UNIV

Biological control composition

PCT designated stageWO2026003295A1BiocideFungicidesLysinBiochemistry
Disclosed is a biological control composition comprising a known molar amount of bacilysin, or a known and high ratio of bacilysin to fengycin, uses of said composition, a method for purifying bacilysin and a method for absolute quantification of bacilysin.
Owner:BIOCSOL SRL

Bacterial lysins and uses thereof

PendingUS20260183372A1BiotechnologyLysin
A general formula for lysins based on which the activity and functionality are further screened and 24 lysins are identified and further investigated, nine of which are characterized. These lysins exhibit potent bactericidal activity, capable of lysing multiple species of Staphylococcus, Streptococcus, and / or Enterococcus; demonstrate robust environmental resistance and stability, retaining activity under varying temperatures, NaCl concentrations, pH levels, and in immune serum; and effectively treat localized and systemic infections. These lysins and their variants are promising as antimicrobial agents for eradicating bacteria, preventing bacterial infections, or treating bacterial infections (caused by genera Staphylococcus, Streptococcus, and / or Enterococcus).
Owner:HUAZHONG AGRI UNIV

Intravaginal formulations of gardnerella endolysin

The present invention relates to a novel pharmaceutical composition comprising an effective amount of an active agent and a pharmaceutically acceptable excipient wherein the active agent is a polypeptide having killing activity against Gardnebacterium genus, and wherein the excipient is a polyacrylic acid polymer. The invention also relates to the use of the pharmaceutical composition in the treatment of Gardnebacterium infections, in particular bacterial vaginosis.
Owner:BIONTECH SE

Improved Synthesis of Acetylsalicylic Acid Lysine-Glycine Particles

The present invention provides an improved method for preparing acetylsalicylic acid lysine glycine (LASAG) that allows for high yields without the need for the addition of seed crystals, resulting in a controlled small particle size (preferably less than 40 μm median particle size) and high stability of the LASAG. Advantageously, the method can be carried out at room temperature without adversely affecting the yield or particle properties. The present invention also provides LASAG obtained from said method, and its use as a pharmaceutical product.
Owner:ASPIAIR GMBH

Gram-negative bacterium lyase and application thereof

The invention discloses gram-negative bacterium lyase and application thereof, and relates to the technical field of biological medicine. The gram-negative bacterium lyase is a lyase lysin of which the amino acid sequence is as shown in SEQ ID NO.1 or a lyase lysin-Mix of which the amino acid sequence is as shown in SEQ ID NO.3. The gram-negative bacterium lyase is a lyase lysin of which the amino acid sequence is as shown in SEQ ID NO.1. According to the invention, a novel lyase lysin is excavated from a bacteriophage, and the lyase lysin is subjected to bioinformatics analysis and modification, so that a novel lyase, namely lysin-Mix, is prepared. A lyase activity detection experiment shows that the modified new lyase can penetrate through the outer membrane of gram-negative bacteria and has good cracking activity. The invention provides technical support for developing novel antibacterial drugs.
Owner:GUANGZHOU MEDICAL UNIV

Pagrosomus major antibacterial peptide Pm-NK-lysin as well as preparation method and application thereof

The invention relates to the technical field of biology, in particular to a pagrosomus major antibacterial peptide Pm-NK-lysin as well as a preparation method and application of the pagrosomus major antibacterial peptide Pm-NK-lysin. The amino acid sequence of the antibacterial peptide is as shown in SEQ ID NO: 1. The minimum inhibitory concentration of the antibacterial peptide to vibrio anguillarum is not higher than 8 [mu] g / ml, and / or the minimum inhibitory concentration of the antibacterial peptide to escherichia coli is not higher than 4 [mu] g / ml. The antibacterial peptide is prepared through a pichia pastoris expression system. The antibacterial peptide is applied to preparation of an antibacterial preparation. According to the invention, efficient secretory expression of recombinant Pm-NK-lysin is successfully realized by creatively utilizing a pichia pastoris eukaryotic expression system, and a protein purification process is optimized, so that sufficient sources of high-activity recombinant protein are guaranteed. The Pm-NK-lysin provided by the invention has an excellent killing effect on aquatic pathogenic bacteria. The antibacterial peptide Pm-NK-lysin is used for replacing or reducing the use of antibiotics to control the harm of aquatic bacterial diseases, has wide popularization and application values, and certainly has far-reaching significance for promoting the green and healthy development of the aquaculture industry.
Owner:OCEAN UNIV OF CHINA

RNA formulations suitable for therapy

ActiveUS12667621B2DimerMessenger RNA
The present invention relates to compositions comprising RNA, preferably messenger RNA (mRNA), more preferably self-amplifying RNA (saRNA), and polymers, in particular cationic polymers, such as polyethylenimine (PEI), poly-L-Lysin (PEL), polyvinylamine (PVA) or polyallylamine (PAA), where individual RNA molecules are present in solution. In the formulations, the RNA is preferentially present in the form of monomers, dimers, timers or oligomers, but not as aggregates comprising a large number of RNA molecules per aggregate, in particular large polyplex nanoparticles. The formulations display improved transfection efficacy and they can be used for delivery of RNA to a subject, where they have an improved dose response relationship in comparison to formulations where large aggregates in the form of polyplex nanoparticles are present.
Owner:BIONTECH SE

A method, device, medium and equipment for predicting marine phage antibacterial lysin

The application discloses a marine bacteriophage antibacterial lysin prediction method and device, medium and equipment, and relates to the fields of biological medicine and computational biology. The method comprises the following steps: constructing a training data set based on global known antibacterial protein sequences; training a protein sequence classification model based on deep learning by using the antibacterial protein data set to obtain a marine antibacterial lysin prediction model. After data standardization processing, the protein sequence of the bacteriophage to be predicted is input into the protein language model, the input sequence is subjected to self-attention modeling by a ProtT5 module, global structure and function related features are extracted, and a first feature vector is obtained; short sequence local dependency features are extracted by a ProtBERT module, and a second feature vector is obtained; the first and second feature vectors are weighted and summed to generate a fusion feature vector; and the fusion feature vector is subjected to probability prediction, and an antibacterial label and a prediction confidence of the marine bacteriophage sequence to be predicted are output.
Owner:OCEAN UNIV OF CHINA

Alpha spiral mutant of granulysin with improved antibacterial activity and application of alpha spiral mutant

The invention relates to the technical field of agricultural biology, in particular to an alpha spiral mutant of granulysin with improved antibacterial activity and application of the alpha spiral mutant. The amino acid sequence of the alpha spiral mutant peptide of granulysin with improved antibacterial activity is as shown in SEQ ID No: 2. According to the present invention, the antibacterial activity of the granulysin mutant on different bacteria such as gram-negative bacteria salmonella typhimurium, escherichia coli and salmonella pullorum is enhanced;
Owner:INSTITUTE OF ANIMAL SCIENCES OF CHINESE ACADEMY OF AGRICULTURAL SCIENCES

A quorum sensing self-regulating recombinant Escherichia coli and a method for extracellular preparation of recombinant proteins therefrom

This invention discloses a quorum-sensing self-regulated recombinant *E. coli* and a method for extracellular preparation of recombinant proteins, belonging to the field of genetic engineering technology. In this invention, *E. coli* with self-lysis function is constructed by recombinantly expressing phage lysin E, and this engineered bacterium has the ability to produce extracellular proteins. This invention provides a method for *E. coli* to produce extracellular proteins. Using this self-lysis system, GFP, rhamnosidase, sorbitol dehydrogenase, and lipoxygenase can be efficiently produced extracellularly. Simultaneously, high extracellular production of LOX was achieved in a 5L fermenter using self-lysis *E. coli*, with an enzyme activity reaching 4300 U / ml. This method has important guiding significance for the extracellular production of recombinant proteins in *E. coli*.
Owner:SHENZHEN UNIV

Antibody-conjugates for targeting of tumours expressing trop-2

The present invention concerns antibody-conjugate having general structure (2):wherein AB is an antibody capable of targeting Trop-2-expressing tumours and D is selected from the group consisting of taxanes, anthracyclines, camptothecins, epothilones, mytomycins, combretastatins, vinca alkaloids, maytansinoids, enediynes such as calicheamicins, duocarmycins, tubulysins, amatoxins, bleomycins, dolastatins and auristatins, pyrrolobenzodiazepine dimers, indolinobenzodiazepine dimers, radioisotopes, therapeutic proteins and peptides (or fragments thereof), kinase inhibitors, MEK inhibitors, KSP inhibitors, and analogues or prodrugs thereof. These antibody-conjugates exhibit an improved therapeutic index. The invention further concerns a process for preparing the antibody-conjugate according to the invention, a method for targeting Trop-2-expressing cells, medical uses of the antibody-conjugates according to the invention.
Owner:SYNAFFIX BV

Bacteria expressing lysins for inhibition of methanogenesis

The disclosure relates to compositions and methods of bacterial species expressing endolysins for the prophylaxis and treatment of methanogen growth in the digestive tract of an animal. More specifically, the disclosure relates to agents, compositions, and methods for preventing and / or inhibiting growth of methanogens.
Owner:SILAGE LABS INC

Modified microorganisms

The present invention relates to a live attenuated Gram-negative bacterium comprising a modified hlyCABD operon, wherein the modified hlyCABD operon is split into a first segment and a second segment, the first segment being operably linked to a first independently controlled promoter, wherein the first independently controlled promoter is a strong constitutive promoter or a strong vacuole-induced promoter, and the second segment being operably linked to a second independently controlled promoter, wherein the second independently controlled promoter is a strong vacuole-induced promoter, and wherein the first segment comprises a heterologous polynucleotide encoding a lysin upstream of a hlyAs translocation sequence, wherein the heterologous polynucleotide encoding one or more cargo molecules replaces a hlyA gene, and wherein the second segment comprises hly genes involved in secretion.
Owner:PROKARIUM LTD

A Saccharomyces cerevisiae engineered strain capable of controlled self-lysis and release of astaxanthin and its application

ActiveCN121574965BAstaxanthinAmino acid
This invention provides a *Saccharomyces cerevisiae* strain, HYB05, capable of controlled self-lysis and release of astaxanthin. The engineered strain HYB05 uses a basic astaxanthin-producing strain as the starting strain and incorporates a recombinant nucleic acid construct including the coding sequence of the cell wall lysin Lyc, the coding sequence of the signal peptide mutant F8A, and expression regulatory elements. Simultaneously, the SSD1 gene is knocked out to relieve translational repression. The amino acid sequence of the cell wall lysin Lyc is shown in SEQ ID NO: 6; the amino acid sequence of the signal peptide mutant F8A is shown in SEQ ID NO: 8. By introducing the aforementioned recombinant nucleic acid construct, the engineered strain HYB05 achieves activation of the catalytic activity of the cell wall lysin under specific conditions, resulting in cell wall rupture and the release of synthesized astaxanthin. Using this strain for astaxanthin fermentation simplifies the extraction process, maximizes the extraction of astaxanthin from yeast, significantly increases astaxanthin yield, and demonstrates significant technical benefits.
Owner:QINGDAO AGRI UNIV

PH response type injectable hydrogel loaded with prNK-lysin as well as preparation method and application of pH response type injectable hydrogel

The invention discloses a prNK-lysin loaded pH response type injectable hydrogel as well as a preparation method and application thereof, and belongs to the technical field of clinical veterinary medicine and biochemical materials. The preparation method comprises the following steps: synthesizing a hydrogel carrier DEX / HAGel by using dextran, ethylenediamine and aminated hyaluronic acid (NH2-PEG-HA), and encapsulating prNK-lysin in hydrogel, so as to form prNK-lysin (DEX / HA Gel. The hydrogel has a Schiff base bond with pH response, so that the hydrogel has a controllable prNK-lysin slow release characteristic; the gel can be injected into tumor tissues in a gel form, so that explosive release of prNK-lysin is avoided; nH2-PEG-HA is coupled to the hydrogel material, so that the hydrogel material is specifically combined with a dog breast tumor cell surface receptor, and the enrichment amount of the hydrogel material in tumor tissues is increased.
Owner:SHANXI AGRI UNIV

A formulation of a conjugate of a tubulysin analog to a cell-binding molecule

A formulation of conjugates of tubulysin analogs with a cell-binding molecule having a structure represented by Formula (I), wherein T, L, m, n, , R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, and R13 are as defined herein, can be used for targeted treatment of cancer, autoimmune disease, and infectious disease.
Owner:HANGZHOU DAC BIOTECH CO LTD

Clostridium difficile phage recombinant lysin Lys51, its preparation method and application

PendingCN122326634AEscherichia coliLysin
This invention discloses the Clostridium difficile phage recombinant lyase Lys51, its preparation method, and its application, relating to the field of genetic engineering technology. The invention involves introducing the recombinant plasmid pET-28a-SUMO-Lys51 into Escherichia coli BL21(DE3) competent cells via heat shock transformation; screening to obtain the recombinant engineered bacterium BL21(DE3)-pET-28a-SUMO-Lys51; constructing the recombinant plasmid pET-28a-SUMO-Lys51 and the recombinant engineered bacterium BL21(DE3)-pET-28a-SUMO-Lys51, further inducing the expression of Clostridium difficile phage recombinant lyase Lys51 in the recombinant engineered bacterium BL21(DE3)-pET-28a-SUMO-Lys51, and then purifying it to achieve the complete process for preparing Clostridium difficile phage recombinant lyase Lys51.
Owner:JILIN UNIVERSITY

Antibacterial peptide chicken NK lysin mutant and application thereof

The invention relates to the technical field of agricultural biology, in particular to an antibacterial peptide chicken NK lysin mutant and application thereof. According to the present invention, the antibacterial activity of the chicken NK lysin mutant on different bacteria such as salmonella typhimurium 541, gram-negative bacteria, Escherichia coli O157: H7 1491, gram-negative bacteria, salmonella pullorum of gram-negative bacteria, and Staphylococcus aureus can be enhanced, and the antibacterial activity of the chicken NK lysin mutant on different bacteria such as salmonella typhimurium 541, gram-negative bacteria, Escherichia coli O157: H7 1491, gram-negative bacteria, salmonella pullorum of gram-negative bacteria, and Staphylococcus aureus can be enhanced;
Owner:INSTITUTE OF ANIMAL SCIENCES OF CHINESE ACADEMY OF AGRICULTURAL SCIENCES

A recombinant bacillus calmette-guerin strain and application thereof in preparation of tumor vaccine

The application discloses a recombinant bacillus Calmette-Guerin (BCG) strain and application of the recombinant BCG strain in preparation of a tumor vaccine, wherein the recombinant BCG strain comprises an HPV16 E7 antigen gene with a nucleotide sequence as shown in SEQ ID NO:1; a cytolysin ClyA gene is further fused with the HPV16 E7 to be expressed, and a rBCG-ClyA+E7 recombinant strain is constructed; the recombinant BCG strain rBCG-E7 or rBCG-ClyA+E7 is applied in preparation of a vaccine for treating cervical cancer solid tumors; the anti-tumor effect is verified in a solid tumor model through a subcutaneous injection mode; the ClyA significantly improves the expression efficiency of an exogenous antigen in the BCG, and simultaneously enhances the presentation efficiency of an antigen presenting cell; the recombinant vaccine effectively activates an anti-tumor immune response, and does not cause obvious toxic side effects, thereby providing a safe and effective candidate strategy for immunotherapy of cervical cancer and other HPV related solid tumors.
Owner:INST OF MEDICAL BIOLOGY CHINESE ACAD OF MEDICAL SCI

Formulation of a conjugate of a tubulysin analog to a cell-binding molecule

A formulation of conjugates of tubulysin analogs with a cell-binding molecule having a structure represented by Formula (I), wherein T, L, m, n, ----, R1, R2, R3, R4, R1, R6, R7, R1, R9, R10, R11, R12, and R13 are as defined herein, can be used for targeted treatment of cancer, autoimmune disease, and infectious disease.
Owner:HANGZHOU DAC BIOTECH CO LTD